Aurobindo receives FDA nod for generic Vagifem
Estrodiol vaginal inserts are indicated for the treatment of atrophic vaginitis due to menopause.
The Food and Drug Administration has approved Aubobindo’s estradiol vaginal inserts, 10 mcg, which is the generic of Novo Nordisk’s Vagifem.
The product will be launched in the second quarter of 2025.
[Read more: Aurobindo receives FDA approval for 3 generics]
Estrodiol vaginal inserts are indicated for the treatment of atrophic vaginitis due to menopause.
The approved product had a market value of approximately $268 million for the 12 months ending June 2024, per IQVIA.